tracken
AbCellera Biologics Inc Aktie News
Neutral
Business Wire
●
6 Tage alt
VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera to Participate at Upcoming Investor Conferences in November and December 2025.
Positiv
Seeking Alpha
●
7 Tage alt
AbCellera Biologics is poised for long-term growth as its clinical manufacturing facility nears completion, enabling in-house drug development and contract manufacturing revenue. ABCL's strategic pivot from a service provider to a proprietary drug developer targets high-growth monoclonal antibody markets, with promising candidates ABCL635 and ABCL575 entering clinical trials. Despite recent rev...
Neutral
Business Wire
●
14 Tage alt
VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera to Report Third Quarter 2025 Financial Results on November 6, 2025.
Neutral
Business Wire
●
etwa ein Monat alt
VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera Appoints Dr. Sarah Noonberg as Chief Medical Officer.
Neutral
Business Wire
●
etwa 2 Monate alt
VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera Doses First Participants in a Phase 1 Clinical Trial of ABCL575.
Neutral
Business Wire
●
2 Monate alt
VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera to Participate at Upcoming Investor Conferences in September.
Neutral
Seeking Alpha
●
2 Monate alt
AbCellera Biologics Inc. (NASDAQ:ABCL ) Q2 2025 Earnings Conference Call August 7, 2025 5:00 PM ET Company Participants Andrew Booth - Chief Financial Officer Carl L.G. Hansen - CEO, President & Chairperson Tryn T.
Neutral
Business Wire
●
2 Monate alt
VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera Reports Q2 2025 Business Results & Initiation of a Phase 1 Clinical Trial of ABCL635 for Vasomotor Symptoms.
Kostenlos registrieren
aktien.guide ist das Tool zum einfachen Finden, Analysieren und Beobachten von Aktien. Lerne von erfolgreichen Investoren und triff fundierte Anlageentscheidungen. Wir machen Dich zum selbstbestimmten Investor.
